2022-09-07
Visited : 929
Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles (LNP).
As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patients with rare liver diseases.
“We are building a robust, proprietary portfolio of genomic medicines, beginning with severe liver diseases, for which LNPs are known to provide an optimal delivery approach with their ability to efficiently target hepatocytes, limit off target toxicity and have minimal immunogenicity. We are looking forward to working with Acuitas, a leading global developer of clinically-validated LNP technology,” said Devyn Smith, Ph.D., CEO, Arbor Biotechnologies. “Importantly, we believe this partnership accelerates our path to the clinic, with an ability to leverage established and scalable manufacturing.”
Commented Dr. Thomas Madden, President & CEO of Acuitas Therapeutics: “We are excited to collaborate with Arbor on the development of novel genomic medicines for patients who currently have few, if any, therapeutic options. Arbor’s commitment to addressing this unmet clinical need resonates with Acuitas. We look forward to supporting their advance into the clinic.”
Read the original article on GlobeNewswire.